Fundraising Fox
Enoda
London · Founded 2021 · Incorporated in United Kingdom · 9 employees on LinkedIn · 2 known investors
Find your way into Enoda
Sign up to see every warm intro you have to Enoda
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Enoda team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Enoda develops synthetic cytokine receptors, called MIMICs, that link therapeutic "Signal 3" cytokine functions to controllable inputs to engineer cell therapies without systemic toxicity. It offers a platform and discovery screens to optimize CAR T cells, regulatory T cells, macrophages, and stem cells for autologous, allogenic, and in vivo cell therapy partners.
Founders & leadership
Enoda was founded in 2021 by Andrew John Scobie, Michael Chavez, and Paul B. Finn.
Board
Investors · 2
How we know: Fifty Years's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: MBX Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountpre-Series AJul 2022Source ↗
▶Undisclosed amountofferedFeb 2025 · Other TechnologyRule 506(b)
- Jennifer UrquhartExecutive Officer, Director
- Jacqueline Elizabeth PorchExecutive Officer, Director
- Charles Louis WatsonDirector
- Andrew John ScobieExecutive Officer, Director
- Lindsay James WhitelawExecutive Officer, Director
- Incorporated
- Other, United Kingdom, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Enoda do?
- Enoda develops synthetic cytokine receptors, called MIMICs, that link therapeutic "Signal 3" cytokine functions to controllable inputs to engineer cell therapies without systemic toxicity. It offers a platform and discovery screens to optimize CAR T cells, regulatory T cells, macrophages, and stem cells for autologous, allogenic, and in vivo cell therapy partners.
- Who founded Enoda?
- Enoda was founded by Andrew John Scobie, Michael Chavez, Paul B. Finn in 2021.
- Who are Enoda's investors?
- Enoda's investors include Fifty Years, MBX Capital.
- Where is Enoda headquartered?
- Enoda is headquartered in London.